Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

The Lancet

Volumn 375, Issue 9722, 2010, Pages 1278-1286

  Walker, AS ^a   Ford, D ^a   Gilks, CF ^b   Munderi, P ^c   Ssali, F ^d   Reid, A ^e   Katabira, E ^f   Grosskurth, H ^c   Mugyenyi, P ^d   Hakim, J ^e   Darbyshire, JH ^a   Gibb, DM ^a   Babiker, AG ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^f MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; HEMOGLOBIN; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; TENOFOVIR DISOPROXIL;

ADULT; AFRICA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MOTIVATION; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK REDUCTION; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 77950630471     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60057-8     Document Type: Article

References (34)

1. Bloland P.B., Redd S.C., Kazembe P., Tembenu R., Wirima J.J., and Campbell C.C. Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet 337 (1991) 518-520
2. Jones J.L., Hanson D.L., Dworkin M.S., et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 48 (1999) 1-22
3. Carr A., Tindall B., Brew B.J., et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 117 (1992) 106-111
4. Anglaret X., Chêne G., Attia A., et al., the Cotrimo-CI study group. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 353 (1999) 1463-1468
5. Wiktor S.Z., Sassan-Morokro M., Grant A.D., et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 353 (1999) 1469-1475
6. Badri M., Ehrlich R., Wood R., and Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 15 (2001) 1143-1148
7. Chintu C., Bhat G.J., Walker A.S., et al., on behalf of the CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364 (2004) 1865-1871
8. Grimwade K., Sturm A.W., Nunn A.J., Mbatha D., Zungu D., and Gilks C.F. Effectiveness of co-trimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 19 (2005) 163-168
9. Mermin J., Lule J., Ekwaru J.P., et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364 (2004) 1428-1434
10. Nunn A.J., Mwaba P., Chintu C., Mwinga A., Darbyshire J.H., and Zumla A. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 337 (2008) a257
11. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach (2006). http://www.who.int/hiv/pub/guidelines/ctx/en/index.html (accessed Feb 28, 2010).
12. Ledergerber B., Mocroft A., Reiss P., et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 344 (2001) 168-174
13. de Quiros J.L.B., Miro J.M., Pena J.M., et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 344 (2001) 159-167
14. Lowrance D., Makombe S., Harries A., et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering co-trimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 46 (2007) 56-61
15. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 (2010) 123-131
16. Division of AIDS. Table for grading severity of adult adverse experiences (1992), National Institute of Allergy and Infectious Diseases, Bethesda, USA
17. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003). http://www.who.int/3by5/publications/documents/arv_guidelines/en/index.h tml (accessed Feb 28, 2010).
18. DART. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS 22 (2008) 237-247
19. Robins J.M., Hernan M.A., and Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 11 (2000) 550-560
20. Hess K.R. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 13 (1994) 1045-1062
21. 3 who discontinue co-trimoxazole have increased risk of malaria and diarrhea. Conference on Retroviruses and Opportunistic Infections 2009; Montreal, Canada; Feb 8-11, 2009. Abstr 33.
22. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008) 924-926
23. Mulenga V., Ford D., Walker A.S., et al. Effect of co-trimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 21 (2007) 77-84
24. WHO. WHO case definitions for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children (2006). http://www.who.int/hiv/pub/guidelines/hivstaging/en/index.html (accessed Feb 28, 2010).
25. Forgacs P., Wengenack N.L., Hall L., Zimmerman S.K., Silverman M.L., and Roberts G.D. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 53 (2009) 4789-4793
26. Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12 (2006) 1365-1371
27. Jiang W., Lederman M.M., Hunt P., et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 199 (2009) 1177-1185
28. Baker C.A., Emenyonu N., Ssewanyana I., et al. Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. AIDS Res Hum Retroviruses 23 (2007) 900-905
29. Glencross D.K., Janossy G., Coetzee L.M., et al. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom 74 suppl 1 (2008) S131-S140
30. Koblavi-Deme S., Maran M., Kabran N., et al. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. AIDS 17 suppl 3 (2003) S17-S22
31. Lawn S.D., Harries A.D., Anglaret X., Myer L., and Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22 (2008) 1897-1908
32. Stringer J.S., Zulu I., Levy J., et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296 (2006) 782-793
33. Zachariah R., Fitzgerald M., Massaquoi M., et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20 (2006) 2355-2360
34. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824